pf-3758309 and danusertib

pf-3758309 has been researched along with danusertib* in 1 studies

Other Studies

1 other study(ies) available for pf-3758309 and danusertib

ArticleYear
Inhibitors of Signaling Pathways That Block Reversal of HIV-1 Latency.
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:2

    Signaling pathways play a key role in HIV-1 latency. In this study, we used the 24ST1NLESG cell line of HIV-1 latency to screen a library of structurally diverse, medicinally active, cell permeable kinase inhibitors, which target a wide range of signaling pathways, to identify inhibitors of HIV-1 latency reversal. The screen was carried out in the absence or presence of three mechanistically distinct latency-reversing agents (LRAs), namely, prostratin, panobinostat, and JQ-1. We identified inhibitors that only blocked the activity of a specific LRA, as well as inhibitors that blocked the activity of all LRAs. For example, we identified 12 inhibitors targeted toward protein kinase C or downstream kinases that blocked the activity of prostratin. We also identified 12 kinase inhibitors that blocked the reversal of HIV-1 latency irrespective of the LRA used in the screen. Of these, danusertib, an Aurora kinase inhibitor, and PF-3758309, a PAK4 inhibitor, were the most potent. The 50% inhibitory concentrations in the 24ST1NLESG cells ranged from 40 to 147 nM for danusertib (selectivity indices, >150) and from 0.1 to 1 nM for PF-3758309 (selectivity indices, >3,300). Both danusertib and PF-3758309 inhibited latency reversal in CD4

    Topics: Anti-HIV Agents; Benzamides; CD4-Positive T-Lymphocytes; Cell Line; HIV Infections; HIV-1; Humans; Pyrazoles; Pyrroles; Signal Transduction; Virus Activation

2019